Mecamylamine – a nicotinic acetylcholine receptor antagonist with potential for the treatment of neuropsychiatric disorders

Antidepressant-like effects of nicotine and mecamylamine in the mouse forced swim and tail suspension tests: role of strain, test and sex

(2009) Jesper T. Andreasen et al.   BEHAVIOURAL PHARMACOLOGY

Varenicline Reduces Alcohol Self-Administration in Heavy-Drinking Smokers

(2009) Sherry A. McKee et al.   BIOLOGICAL PSYCHIATRY

Varenicline Augmentation in Depressed Smokers

(2009) Noah S. Philip et al.   JOURNAL OF CLINICAL PSYCHIATRY

Mammalian Nicotinic Acetylcholine Receptors: From Structure to Function

(2009) Edson X. Albuquerque et al.   PHYSIOLOGICAL REVIEWS

TC-5214 (S-(+)-Mecamylamine): A Neuronal Nicotinic Receptor Modulator with Antidepressant Activity

(2008) Patrick M. Lippiello et al.   CNS Neuroscience & Therapeutics

Nicotinic Antagonist Augmentation of Selective Serotonin Reuptake Inhibitor-Refractory Major Depressive Disorder

(2008) Tony P. George et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Differential Pharmacologies of Mecamylamine Enantiomers: Positive Allosteric Modulation and Noncompetitive Inhibition

(2008) N. B. Fedorov et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Evidence for a Complex Influence of Nicotinic Acetylcholine Receptors on Hippocampal Serotonin Release

(2003) Paul J. Kenny et al.   JOURNAL OF NEUROCHEMISTRY